Loading
AR-V7 is a shortened androgen receptor that lacks the part hormone drugs bind, so it stays active without testosterone. Found in circulating tumour cells, it predicts poor response to abiraterone and enzalutamide, but no label uses it yet.
The AR-V7 transcript skips the ligand-binding domain and is detected by RT-PCR of circulating tumour cell RNA or by nuclear AR-V7 protein immunofluorescence in CTCs (the Oncotype DX AR-V7 Nucleus Detect assay, a laboratory-developed test). The prospective PROPHECY trial (NCT02269982) showed that AR-V7-positive men had shorter progression-free and overall survival on abiraterone or enzalutamide, while taxane response was preserved. No regulator has put AR-V7 in a label and no companion diagnostic exists; it is a guideline-discussed, not guideline-mandated, test.
In plain words · The hormone switch that drives prostate cancer, attacked by castration and by pills that block the receptor.
An AR-V7-positive result suggests that abiraterone and enzalutamide are less likely to work and that chemotherapy or a radioligand may be a better next step, but no approval depends on it and it is not routinely offered outside specialist centres. A negative result does not guarantee response.
Written only from the label or guideline text cited on this page. Not medical advice; your own report and the reading your team gives it come first.
Detection of the AR-V7 transcript in circulating tumour cell RNA by RT-PCR, or nuclear-localised AR-V7 protein in circulating tumour cells by immunofluorescence; no label defines a threshold.
“AR-V7 splice variant”
PROPHECY trial (NCT02269982): prospective validation of AR-V7 in metastatic castration-resistant prostate cancerNo approval uses this readout as a threshold. It is defined by PROPHECY: AR-V7 in circulating tumour cells predicting resistance to abiraterone and enzalutamide (ClinicalTrials.gov NCT02269982).
Matched on the name and aliases of the readout in the title, setting and summary of each trial; a match is a mention, not proof the readout was an entry criterion.
It turned a single-centre observation into a prospectively validated one and concluded that AR-V7-positive men should be offered alternatives to abiraterone and enzalutamide. It also quantified the honest limit: two assays for the same analyte disagree on nearly one sample in five.
It is the clearest evidence in prostate cancer that a blood biomarker can point to one treatment class over another, and the reason AR-V7 is discussed in guidelines despite being in no label.
The first predictive resistance biomarker in prostate cancer, and a mechanism rather than a correlation: a receptor with no ligand-binding domain cannot be blocked by a drug that binds the ligand-binding domain. It is also the origin of the case for androgen receptor degraders, which destroy the protein rather than blocking a site the protein no longer has.
Shares AR amplification (gene and upstream enhancer), Androgen receptor, Metastatic castration-resistant prostate cancer, Prostate cancer and the tags biomarker, prostate.
Shares Androgen receptor, Prostate cancer and the tags biomarker, prostate.
Shares Androgen receptor, Prostate cancer and the tags biomarker, prostate.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tags biomarker, prostate.
Shares the tags biomarker, no-approval.
Shares the tags biomarker, no-approval.
Shares the tags biomarker, no-approval.
Shares the tags biomarker, no-approval.